Previous studies of John et al. revealed that GSK-3β inhibition prevent melanoma cell migration by downregulating the expression of N-cadherin and focal adhesion kinase (FAK) phosphorylation [60] indicating the possibility of using fisetin as therapeutic agent for metastatic melanoma. The gene discussed is CDH2; the disease is metastatic melanoma.